



HAL
open science

Astrocytic DLL4-NOTCH1 signaling pathway promotes neuroinflammation via the IL-6-STAT3 axis.

Pierre Mora, Margaux Laisné, Célia Bourguignon, Paul Rouault, Béatrice Jaspard-Vinassa, Marlène Maître, Alain-pierre Gadeau, Marie-ange Renault, Sam Horng, Thierry Couffinhal, et al.

► To cite this version:

Pierre Mora, Margaux Laisné, Célia Bourguignon, Paul Rouault, Béatrice Jaspard-Vinassa, et al.. Astrocytic DLL4-NOTCH1 signaling pathway promotes neuroinflammation via the IL-6-STAT3 axis.. Journal of Neuroinflammation, 2024, 21 (1), pp.258. 10.1186/s12974-024-03246-w . hal-04739078

HAL Id: hal-04739078

<https://hal.science/hal-04739078v1>

Submitted on 16 Oct 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License

RESEARCH

Open Access



Astrocytic DLL4-NOTCH1 signaling pathway promotes neuroinflammation via the IL-6-STAT3 axis

Pierre Mora¹, Margaux Laisné¹, Célia Bourguignon¹, Paul Rouault¹, Béatrice Jaspard-Vinassa¹, Marlène Maître², Alain-Pierre Gadeau¹, Marie-Ange Renault¹, Sam Horng³, Thierry Couffignal¹ and Candice Chapouly^{1*}

Abstract

Under neuroinflammatory conditions, astrocytes acquire a reactive phenotype that drives acute inflammatory injury as well as chronic neurodegeneration. We hypothesized that astrocytic Delta-like 4 (DLL4) may interact with its receptor NOTCH1 on neighboring astrocytes to regulate astrocyte reactivity via downstream juxtacrine signaling pathways. Here we investigated the role of astrocytic DLL4 on neurovascular unit homeostasis under neuroinflammatory conditions. We probed for downstream effectors of the DLL4-NOTCH1 axis and targeted these for therapy in two models of CNS inflammatory disease. We first demonstrated that astrocytic DLL4 is upregulated during neuroinflammation, both in mice and humans, driving astrocyte reactivity and subsequent blood-brain barrier permeability and inflammatory infiltration. We then showed that the DLL4-mediated NOTCH1 signaling in astrocytes directly drives IL-6 levels, induces STAT3 phosphorylation promoting upregulation of astrocyte reactivity markers, pro-permeability factor secretion and consequent blood-brain barrier destabilization. Finally we revealed that blocking DLL4 with antibodies improves experimental autoimmune encephalomyelitis symptoms in mice, identifying a potential novel therapeutic strategy for CNS autoimmune demyelinating disease. As a general conclusion, this study demonstrates that DLL4-NOTCH1 signaling is not only a key pathway in vascular development and angiogenesis, but also in the control of astrocyte reactivity during neuroinflammation.

Keywords Neuroinflammation, DLL4-NOTCH1 signaling pathway, Reactive astrocytes, IL-6-STAT3 axis

Background

Proper function of the healthy central nervous system (CNS) requires the selective regulation of soluble factors and immune cells through the blood–brain barrier [1]. Blood-brain barrier structure and integrity involves a complex network of crosstalk among various components of the neurovascular unit, including vascular endothelial cells, pericytes, microglia and astrocytes [2].

Substantial intercellular communication occurs between endothelial cells and the astrocyte endfeet of the blood-brain barrier [1, 3]. We recently identified a capacity for bidirectional signaling between

*Correspondence:

Candice Chapouly
candice.chapouly@inserm.fr

¹Univ. Bordeaux, INSERM, Biology of Cardiovascular Diseases, U1034, 01 avenue de Magellan, Pessac 33601, France

²Univ. Bordeaux, INSERM, Neurocentre Magendie, U1215, Bordeaux F-33000, France

³Department of Neurology and Neuroscience, Icahn School of Medicine at Mount Sinai, New York City, NY, USA



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>.

endothelial cells and astrocytes in the neurovascular unit [4]. How these signals contribute to cerebrovascular impairment, blood-brain barrier dysfunction and neuroinflammation remains unclear and carries translational implications for autoimmune demyelinating diseases, stroke and other CNS inflammatory conditions.

Under neuroinflammatory conditions, astrocytes acquire a reactive phenotype. Astrocyte reactivity is a spectrum of potential changes, ranging from reversible alterations in gene expression and protein levels, to altered morphology, cell proliferation, and tissue rearrangement. Common features exist across different forms and intensities of astrocyte reactivity, but even these occur along a gradient that can vary immensely. Thus, astrocyte reactivity is complex, context-dependent, and a multivariate phenomenon that depends on various factors such as the type, severity, and time frame of insult, the CNS location, and the types and combinations of molecular triggers driving the heterogeneity of individual reactive astrocytes [5]. For instance, during infections (HIV, Herpes virus), and in Alzheimer's disease, multiple sclerosis and Parkinson's disease, reactive astrocytes produce both pro-inflammatory factors such as ET-1, glutamate, IL-1 β , TNF and NO and neuroprotective factors such as NGF and glial cell line-derived neurotrophic factors [6]. We previously identified that reactive astrocytes induce blood-brain barrier opening in inflammatory conditions via production of VEGFA and TYMP [7] which downregulate the endothelial tight junction proteins that protect the blood-brain barrier in the healthy brain [8].

NOTCH1 receptor is a central effector of astrocyte reactivity in a wide range of neuropathological contexts. After intra-cerebral hemorrhage [9], in stroke [10] and in several neuroinflammatory conditions such as amyotrophic lateral sclerosis [11], multiple sclerosis and experimental auto-immune encephalomyelitis (EAE) [12, 13], NOTCH1 signal transduction is activated in reactive astrocyte populations.

Notch signaling, which is highly conserved in vertebrates, is stimulated by the interaction of Notch receptor with its ligands, Delta and Jagged, trans-membrane proteins with large extracellular domains. Ligand binding promotes two proteolytic cleavages in the Notch receptor: the first catalysed by ADAM-family metalloproteases and the second mediated by γ -secretase [14–16]. The second cleavage releases the Notch intracellular domain (NICD), which translocates to the nucleus and cooperates with the DNA-binding protein CSL (named after CBF1, Su(H) and LAG-1) to promote transcription. The precise numbers of NOTCH receptors differ between species [17]: in vertebrates, 4

different NOTCH receptors have been identified and in the neurovascular unit, NOTCH1 is expressed by astrocytes and endothelial cells, NOTCH4 by endothelial cells [18–20] and NOTCH3 by mural cells, or pericytes [21, 22].

Interestingly, activation of the NOTCH1-STAT3 axis in EAE has been shown to control the production of inflammatory cytokines by reactive astrocytes via the long non-coding (lnc) RNA Gm13568, which has also been implicated in MS pathogenesis. Precisely, knock-down of the endogenous lncRNA Gm13568 remarkably inhibits the NOTCH1 expression, astrocytosis, and the phosphorylation of STAT3 as well as the production of inflammatory cytokines and chemokines (IL-6, TNF- α , IP-10) in IL-9-reactive astrocytes. More importantly, inhibiting Gm13568 with lentiviral vector in astrocytes ameliorates significantly inflammation and demyelination in EAE mice, therefore delaying the EAE process [13]. Moreover, the NOTCH1-STAT3 pathway has similarly been identified as an effector of inflammation-induced differentiation of neurotoxic A1 astrocytes in a model of spinal cord injury (SCI) and glial scar formation [23, 24].

As opposed to the abundant literature on the role of NOTCH1 receptor, DLL4 ligand expression has only been reported once, anecdotally, in reactive astrocytes, following brain injury [25]. The important role of DLL4-NOTCH1 signaling in the cardiovascular system is already widely appreciated [26], but little is known about this specific pathway in reactive astrocyte reactivity during neuroinflammation.

We hypothesized that astrocytic DLL4 may interact with the receptor NOTCH1 on neighboring astrocytes to regulate astrocyte reactivity and neuroinflammation via downstream juxtacrine signaling pathways.

We first tested the role of astrocytic DLL4 on neurovascular unit homeostasis under neuroinflammatory conditions. We then probed for downstream effectors of the DLL4-NOTCH1 axis and targeted these for therapy in two models of CNS inflammatory disease. Here, we demonstrate that astrocytic DLL4 is upregulated during neuroinflammation, both in mice and humans, driving astrocyte reactivity and subsequent blood-brain barrier permeability and inflammatory soluble factor and immune cell infiltration. We then show that the DLL4-mediated NOTCH1 signaling in astrocytes directly drives IL-6 levels, induces STAT3 phosphorylation promoting upregulation of astrocyte reactivity markers, pro-permeability factor secretion and consequent blood-brain barrier destabilization. Finally we reveal that blocking DLL4 with antibodies improves EAE symptoms in mice, identifying a potential novel therapeutic strategy for CNS autoimmune demyelinating disease.




Fig. 1 (See legend on next page.)

(See figure on previous page.)

Fig. 1 DLL4 is expressed by CNS astrocytes and upregulated during chronic neuroinflammation. **(A–D)** Human astrocytes (NA) were cultured until confluence, starved for 24 h and treated for 24 h with PBS 1X (control) versus 10 ng/mL of recombinant IL-1 β . **(A)** *DLL4* and **(B)** *VIM* expression were quantified by qRT-PCR. β -*ACTIN* was used as a reference ($n=6$). **(C)** Representative western blot (WB) for *DLL4* and β -*ACTIN* (ACTB) protein expression level are shown. **(D)** *DLL4* protein expression level was quantified by western blot. ACTB was used as a reference. ($n=6$). **(E–G)** *C57BL/6* females (4 animals/group) were induced with EAE versus Freund adjuvant alone (Ctrl). At day 13 post induction, mice were sacrificed and spinal cord neurovascular units were isolated. **(E)** *Dll4*, **(F)** *Hey1*, and **(G)** *Jag1* expression were measured via qRT-PCR in both groups (MOG_{35–55} versus Ctrl) ($n=4$). **(H)** Spinal cord sections were harvested from MOG_{35–55} EAE-induced versus Ctrl *C57BL/6* females and immuno-stained with anti-DLL4 (in red) and anti-GFAP (in green) antibodies. Representative *DLL4*/GFAP staining is shown. **(I)** *DLL4* positive areas were quantified (Ctrl mice $n=6$ and MOG_{35–55} EAE-induced mice $n=6$). **(J)** Human cortical sections from non-pathological donors and patients with MS lesions were immunostained with anti-DLL4 (in green) and anti-GFAP (in red) antibodies. Nuclei were stained with DAPI (in blue). Representative *DLL4*/GFAP staining is shown. *DLL4* quantification in the human cortical sections cannot be provided as the number of samples available (3 /group) limits us. **(K)** 12-week-old *C57BL/6* females were induced with EAE. At day 5, 11, 18 and 24 post induction, mice were sacrificed (4–5 animals per group) and spinal cord cervical, thoracic and lumbar sections were harvested and immuno-stained with anti-DLL4 and anti-GFAP antibodies. *DLL4* positive areas in the 3 sections were quantified at each time point. Statistical significance was determined by using a Mann-Whitney U test or 2 ways Anova followed by Holm-Sidak's multiple comparisons test

In summary, we report here for the first time that the *DLL4*-*NOTCH1* axis acts as a key driver of astrocyte reactivity during neuroinflammation via upregulation of the *IL-6*-*STAT3*-*TYMP*/*VEGFA* signaling pathway, leading to disruption of the neurovascular unit, increased immune infiltration into the CNS parenchyma and worsened neuropathology. More generally, this study demonstrates that *DLL4*-*NOTCH1* signaling is not only a key pathway in vascular development and angiogenesis [27], but also in the control of astrocytic reactivity during neuroinflammation.

Results

DLL4 is expressed by CNS astrocytes and upregulated during chronic neuroinflammation

First, we showed that *DLL4* is strongly upregulated in reactive astrocytes under inflammatory conditions in vitro using CNS normal human astrocytes (NA) from ScienCell treated with IL-1 β (interleukin-1 β), a central pro-inflammatory cytokine driving multiple sclerosis pathophysiology (Fig. 1, A, C–D) and in vivo (Fig. 1, E), in the neurovascular unit, using experimental autoimmune encephalomyelitis (EAE), a pre-clinical model of multiple sclerosis using MOG_{35–55} to induce chronic neuroinflammation in *C57BL/6* mice. For this experiment, isolated spinal cord micro-vessels underwent a digestion step followed by a CD45⁺ T cell depletion step to eliminate inflammatory cell infiltrates induced by EAE. *DLL4* upregulation in human reactive astrocytes in vitro is associated with upregulation of the astrocyte reactivity marker *VIM* (Vimentin) (Fig. 1, B). *Dll4* upregulation in the neurovascular unit is associated with upregulation of Notch signaling activation markers *Hey1* (hairy/enhancer-of-split related with YRPW motif protein 1) and *Jag1* (jagged 1) (Fig. 1, F–G). We then confirmed that *DLL4* is upregulated in reactive astrocytes in vivo, on spinal cord sections from EAE induced *C57BL/6* adult mice (Fig. 1, H–I) and on cortical active lesions from multiple sclerosis patients (Fig. 1, J). In addition, we measured astrocytic *DLL4* expression level in cervical, thoracic and lumbar

spinal cord sections from EAE induced *C57BL/6* adult mice at different time points (day 0, 5, 11, 18 and 24 post immunization). We showed that astrocytic expression of *DLL4* is predominant at the thoracic level of the spinal cord in the early stage of EAE (day 5 post immunization), before increasing at the cervical level of the spinal cord in the late stages of EAE (day 11 and 18 post immunization). *DLL4* remains weakly expressed by astrocytes at the lumbar level of the spinal cord regardless of the post immunization time point (Fig. 1, K).

Inactivation of astrocyte *Dll4* reduces disability in a model of multiple sclerosis during the onset and plateau of the disease

To test the role of astrocyte *DLL4* in neuroinflammation, we conditionally disrupted *Dll4* expression in astrocytes using 2 different promoters (the *Glast-Cre^{ERT2}* promoter and the *Aldh1L1-Cre^{ERT2}* promoter) and examined the consequences on EAE pathology. Experimental mice consisted of *Glast-Cre^{ERT2}*, *Dll4^{Flox/Flox}* mice or *Aldh1L1-Cre^{ERT2}*, *Dll4^{Flox/Flox}* mice with corresponding littermate controls (*Dll4^{Flox/Flox}*). We first verified the efficiency of both knockouts, 4 months after inducing knockdown by intra-peritoneal injection of tamoxifen. The *Glast-Cre^{ERT2}* promoter induced a moderate recombination (30–50%) whereas the *Aldh1L1-Cre^{ERT2}* promoter induced a full recombination (90–100%) in both spinal cord and cortical astrocytes (Supplemental Fig. 1, A–H). The difference in recombination efficiency enabled us to test the effects of partial versus complete astrocyte *Dll4* knockdown in the disease course and spinal cord pathology of experimental multiple sclerosis (EAE).

In the rest of the manuscript, *Glast-Cre^{ERT2}*, *Dll4^{Flox/Flox}* mice will be named *Dll4^{ACKO P}* (for partial recombination) and *Aldh1L1-Cre^{ERT2}*, *Dll4^{Flox/Flox}* mice will be named *Dll4^{ACKO C}* (for complete recombination) to make reading easier.

We confirmed the absence of *DLL4* astrocyte expression in non-reactive astrocytes in *Dll4^{ACKO C}* mice versus




Fig. 2 (See legend on next page.)

(See figure on previous page.)

Fig. 2 Inactivation of astrocytic *Dll4* reduces disability during the onset and plateau of EAE disease. **(A)** *Dll4*^{ACKOP} mice and *control* mice induced with EAE were scored daily according to a widely-used 5-point scale (EAE scoring: 1 limp tail; 2 limp tail and weakness of hind limb; 3 limp tail and complete paralysis of hind legs; 4 limp tail, complete hind leg and partial front leg paralysis). Statistical significance was determined by using a 2 ways Anova test followed by the Holm-Sidak's multiple comparisons test (*: $p \leq 0.05$; **: $p \leq 0.01$; ***: $p \leq 0.001$ ****: $p \leq 0.0001$). (*Dll4*^{ACKOP} $n=10$, WT $n=9$). **(B)** *Dll4*^{ACKOP} and *control* mice EAE peak score and **(C)** EAE average score during time of disability (mice present symptoms) were quantified other the course of the disease. **(D)** *Dll4*^{ACKOC} mice and *control* mice induced with EAE were scored daily on a standard 5-point scale, two ways Anova. (*Dll4*^{ACKOC} $n=15$, WT $n=15$). **(E)** *Dll4*^{ACKOC} and *control* mice EAE peak score and **(F)** EAE average score during time of disability were quantified other the course of the disease. **(G-J)** Non-pathologic spinal cord tissues and spinal cord EAE lesions from *Dll4*^{ACKOP} mice, *Dll4*^{ACKOC} mice and littermate *controls* were harvested at 18 days post induction. **(G-H)** *Dll4*^{ACKOP} mice and *control* lesions (low magnification images) and **(I-J)** *Dll4*^{ACKOC} mice and *control* lesions (low magnification images) were immuno-stained with an anti-MBP (in green) antibody. **(H, J)** White matter MBP positive areas were quantified (the white matter (WM) is delimited from the grey matter (GM) by the white dotted lines). **(H)** (Non-pathologic tissues: *Dll4*^{ACKOP} mice $n=4$, WT $n=4$; EAE tissues: *Dll4*^{ACKOP} mice $n=5$, WT $n=6$), **(J)** (Non-pathologic tissues: *Dll4*^{ACKOC} mice $n=4$, WT $n=4$; EAE tissues: *Dll4*^{ACKOC} mice $n=6$, WT $n=7$). Statistical significance was determined by using a Mann-Whitney U test

control littermates (Supplemental Fig. 1, I) and highlighted astrocyte specific DLL4 downregulation in EAE induced *Dll4*^{ACKOC} mice versus *control* littermates (Supplemental Fig. 1, J) and in *Dll4*^{ACKOP} mice versus *control* littermates injected in the cortex with AdIL-1 β (Supplemental Fig. 1, K)), another mouse model of astrocyte reactivity and CNS autoinflammation.

In the *Dll4*^{ACKOP} mouse model, *littermate control* mice demonstrated neurologic deficits from day 11, which increased in severity until day 21, when the clinical score stabilized at a mean of 3.0, representing hind limb paralysis. In contrast, the clinical course in *Dll4*^{ACKOP} mice was much milder: disease reached a plateau at day 27 at a mean of 2.5, indicating hind limb weakness and unsteady gait, a milder phenotype (Fig. 2, A). The EAE peak score (Fig. 2, B) was no different between the groups but average score during the time of disability (Fig. 2, C) was decreased in *Dll4*^{ACKOP} mice.

In the *Dll4*^{ACKOC} mouse model, *littermate control* mice exhibited neurologic deficits from day 12, which increased in severity until day 20, when clinical score stabilized at a mean of 2.8, representing hind limb paralysis. In contrast, the onset of clinical signs in *Dll4*^{ACKOC} mice was first seen four days later, and the clinical course was very mild. Indeed, in *Dll4*^{ACKOC} mice, disease reached a plateau at day 18 at a mean of 0.4 indicating almost no sign of paralysis (Fig. 2, D). Strikingly, only two *Dll4*^{ACKOC} mice developed very mild symptoms, the remaining majority showing no sign of pathology other the course of the disease. The EAE peak (Fig. 2, E) and average scores during the time of disability (Fig. 2, F) were both strongly decreased in *Dll4*^{ACKOC} mice.

Clinical course in both *Dll4*^{ACKOP} mice and *Dll4*^{ACKOC} mice was correlated with decreased areas of demyelination as compared to the *control* cohorts (Fig. 2, G-J).

In sum, we found that clinical course and pathology of EAE are reduced in mice with astrocyte *Dll4* knockdown. Furthermore, degree of *Dll4* knockdown appeared to have a dose-dependent effect as reduced

pathology was only observed during the onset of the disease in the *Dll4*^{ACKOP} mice while reduced pathology was observed during both the onset and plateau of the disease in the *Dll4*^{ACKOC} mice. Moreover, the magnitude of the protective effect of *Dll4* astrocyte knockdown was stronger in *Dll4*^{ACKOC} mice than in *Dll4*^{ACKOP} mice.

Astrocyte-specific *Dll4* inactivation induces downregulation of astrocyte reactivity under neuroinflammatory condition both in vitro and in vivo

To test the importance of astrocyte DLL4 expression in reactive astrocytes during neuroinflammation, we conditionally disrupted DLL4 expression in human astrocytes, and examined the consequences on astrocyte reactivity. To do so, we used human Normal Astrocytes (NA) from ScienCell that we transfected with either a *siRNA control* or a *siRNA* targeting *Dll4* expression. Astrocyte reactivity was then induced using the pro-inflammatory cytokine IL-1 β to induce astrocyte reactivity in vitro.

We first verified the efficiency of the knockdown by measuring DLL4 gene and protein expression in primary human NA cultures transfected with the *siCTRL* versus *siDLL4* and treated with IL-1 β , and showed that DLL4 gene and protein expression were strongly downregulated in the *siDLL4* condition compared to the *siCTRL* condition (Fig. 3, A-C) along with the protein expression of NICD1 (notch1 intracellular domain) which reflects the level of activation of the notch pathway (Fig. 3, D-E). The downregulation of the DLL4-NOTCH1 axis was paired with the downregulation of identified reactive astrocyte markers notably VIM (VIMENTIN) [28] and cleaved CASPASE 3 [29] (Fig. 3, D, F-G). We then confirmed that *Dll4* knockdown leads to disruption of astrocyte reactivity in vivo, on isolated astrocyte lysates from EAE induced *Dll4*^{ACKOP} and *Dll4*^{ACKOC} mice and *control* littermates.

Transcriptional profiling of isolated astrocyte lysates from EAE induced *Dll4*^{ACKOC} and *control* littermates showed that 1558 genes were downregulated in EAE induced *Dll4*^{ACKOC} mice while 874 genes were

upregulated (Supplemental Fig. 2, A). Notably, among the downregulated genes, a wide cohort of transcripts linked to reactive astrocyte markers (Fig. 3, H). Specifically, this approach identified, among others, *Vim* (vimentin) and *Serpina3n* transcripts as downregulated in astrocyte samples from EAE induced *Dll4^{ACKO}* mice (Fig. 3, H). Importantly, these two factors, like all the genes highlighted in the heatmap (Fig. 3, H), have been identified as markers of astrocytic reactivity in the international consensus published in 2021 in the journal *nature neuroscience* [28]. The pro-inflammatory cytokine *Il-6* (interleukin-6) transcripts are also downregulated in astrocyte samples from EAE induced *Dll4^{ACKO}* mice (Fig. 3, H). Surprisingly, *Gfap* transcripts weren't modulated in astrocyte samples from EAE induced *Dll4^{ACKO}* mice (cf. transcriptional profiling of isolated astrocyte lysate full table, additional file 1). However, in examining VIM and GFAP protein expression by western blot, in spinal cord lysates from Freund adjuvant and EAE induced *Dll4^{ACKO}* mice compared to control littermates; we showed that both factors are downregulated in *Dll4^{ACKO}* mice (Fig. 3I-K). Moreover, in examining VIM and GFAP protein expression by immunofluorescence on spinal cord sections from EAE-induced *Dll4^{ACKO}* mice and *control* littermates and from EAE-induced *Dll4^{ACKO}* mice and *control* littermates, we confirmed that both GFAP and VIM expression are decreased in the CNS of astrocyte specific *Dll4* deficient mice (*Dll4^{ACKO}* mice) (Fig. 3, L-N) (Supplemental Fig. 2, B).

These findings indicate astrocytic DLL4 expression contributes to the induction of astrocyte reactivity under neuroinflammatory conditions.

Astrocyte-specific DLL4 activity depends partially on its interaction with astrocytic NOTCH1 receptor in vivo and drives NICD upregulation in astrocytes leading to the upregulation of IL-6 transcripts via a direct interaction with NICD

Next, we explored the signaling factors downstream of DLL4 induced astrocyte reactivity. To test if DLL4 induced astrocyte reactivity depends on its interaction with NOTCH1 receptor in reactive astrocytes; we conditionally disrupted *Notch1* expression in astrocytes using the *Aldh1L1-Cre^{ERT2}* promoter and examined the consequences on EAE pathology. Experimental mice consisted of *Aldh1L1-Cre^{ERT2}*, *Notch1^{Flox/Flox}* mice with corresponding littermate *controls* (*Notch1^{Flox/Flox}*). In the rest of the manuscript, *Aldh1L1-Cre^{ERT2}*, *Notch1^{Flox/Flox}* mice will be named *Notch1^{ACKO}* to make reading easier.

In the *Notch1^{ACKO}* mouse model, *control* mice exhibited neurologic deficits from day 12, which increased in severity until day 22, when clinical

score stabilized at a mean of 2.8, representing hind limb paralysis. In contrast, the clinical course in *Notch1^{ACKO}* mice was much milder: disease reached a plateau at day 20 at a mean of 1.7, indicating hind limb weakness and unsteady gait, a milder phenotype (Fig. 4, A). These results confirm that astrocytic knockouts of *Dll4* or *Notch1* both lead to a decrease in EAE disease progression with recovery of hind limb mobility in knockout animals compared to littermate controls. Thus, these data strongly support our hypothesis that DLL4 is indeed acting through NOTCH1 on reactive astrocytes during neuro-inflammation (Fig. 4, A).

Interestingly, the impact of astrocytic *Notch1* knockout (Fig. 4, A) is more moderate than that of astrocytic *Dll4* knockout (Fig. 2, D) in the context of EAE. This means that astrocytic DLL4 interacts with its NOTCH1 receptor in activated astrocytes, but also potentially with other neighboring cells, via the DLL4-NOTCH signaling, to impact EAE pathology. Given the structure of the neurovascular unit and the inflammatory context associated with EAE, we assume that these neighboring cells might be the lymphocytes infiltrating the CNS parenchyma. This hypothesis remains to be explored and is discussed in the discussion.

Interestingly, NICD has been found to directly regulate IL-6 (interleukin-6) expression in activated macrophages [30] and our transcriptional RNA profiling of astrocyte lysates from EAE induced *Dll4^{ACKO}* and *control* littermates revealed a strong downregulation of *Il-6* transcripts in *Dll4^{ACKO}* samples compared to *controls* (Fig. 3, H). Therefore, we hypothesized that a direct interaction between NICD and IL-6, already observed in reactive macrophages, may contribute to reactive astrocyte reactivity pathways in vitro. To respond to this question, we performed a ChIP experiment on reactive astrocyte lysates using IgG versus NICD antibodies to do the pull down and human *IL-6* primers for the PCR and demonstrated that NICD directly interacts with *IL-6* gene promoter in reactive astrocytes in vitro (Fig. 4, B). Then, to rule out any potential effect of the inflammatory factor IL-1 β on the upregulation of IL-6 in our in vitro model, we transduced non-reactive human astrocytes with a *DLL4* expressing lentivirus versus an *empty* lentivirus. First we validated that the DLL4-NOTCH1 pathway was activated in the astrocyte cultures transduced with the *DLL4* expressing lentivirus, showing the upregulation of *HES1*, *HEY1* and *HEY2* genes (Fig. 4, C-E) and highlighted the concurrent upregulation of *IL-6* expression level (Fig. 4, F). *DLL4* upregulation was also validated to ensure the transduction efficacy (Fig. 4, G).




Fig. 3 (See legend on next page.)

(See figure on previous page.)

Fig. 3 Astrocyte-specific *Dll4* inactivation induces downregulation of astrocyte reactivity under neuroinflammatory condition. **(A-G)** NA were transfected with a *CONTROL siRNA* (20 μ M) versus a *DLL4 siRNA* (20 μ M) and treated with IL-1 β 10ng/mL for 12 h. **(A-C)** DLL4 expression was quantified by **(A)** qRT-PCR ($n=6$) and **(B-C)** WB. β -ACTIN (ACTB) was used as a reference. **(B)** Representative WB for DLL4 and ACTB protein expression are shown. **(C)** DLL4 protein expression was quantified. ($n=6$). **(D-E)** NICD1, **(D, F)** VIM, **(D, G)** cleaved-CASP3 expression were quantified by WB. ACTB and CASP3 total were used as references. ($n=6$) **(H)** Transcriptional RNA profiling of astrocyte lysates from EAE induced *Dll4*^{ACKO}C mice and control littermates was performed. A Heatmap of the differentially expressed genes involved in astrocyte reactivity [28] is shown. **(I-K)** VIM and GFAP protein expression were quantified by WB in spinal cord lysates from Freund adjuvant or EAE-induced *Dll4*^{ACKO}C mice and control littermates (at 18 days post induction). TUBULIN was used as a reference. **(I)** Representative WB for VIM, GFAP and TUBULIN are shown. **(J-K)** VIM and GFAP protein expression were quantified by WB. TUBULIN was used as a reference. (*Dll4*^{ACKO}P mice $n=6$, WT $n=6$) (*Dll4*^{ACKO}C mice $n=6$, WT $n=6$) **(L-N)** Spinal cord EAE lesions from *Dll4*^{ACKO}P mice, *Dll4*^{ACKO}C mice and littermate controls were harvested at 18 days post induction and immuno-stained with anti-GFAP (in green), anti-VIM (in red) and anti-Podocalyxin (PODXL) (in grey) (to discriminate vascular from astrocytic VIM expression) antibodies. Nuclei were stained with DAPI (in blue). **(L)** *Dll4*^{ACKO}C mice versus control tissues are shown. **(M)** GFAP+ and **(N)** VIM+/PODXL- areas were quantified (*Dll4*^{ACKO}P mice $n=6$, WT $n=6$) (*Dll4*^{ACKO}C mice $n=7$, WT $n=7$). Statistical significance was determined by using a Mann-Whitney U test or Kruskal Wallis test followed by the Dunn's multiple comparison test

Altogether, these results suggest that DLL4 driven NOTCH1 activation in reactive astrocytes leads to the upregulation of IL-6 transcripts *via* a direct interaction between NICD and the gene coding for IL-6.

Astrocyte-specific *Dll4* inactivation induces downregulation of astrocyte reactivity through the downregulation of the IL-6-STAT3 pathway both in vitro and in vivo

JAK/STAT (janus kinase/signal transducer and activator of transcription) signaling is an essential effector pathway for the development and regulation of immune responses. Unbridled activation of the JAK/STAT pathway by pro-inflammatory cytokines, notably IL-6, plays a critical role in driving the pathogenesis of multiple sclerosis/EAE [31]. Moreover, STAT3 has been shown to control astrocyte reactivity in various pathologies such as ischemic stroke, neuroinflammatory disorders and brain tumors [32–34]. We tested whether the IL-6-JAK/STAT pathway was regulated by astrocytic *Dll4* in vitro and in vivo. First we showed that both IL-6 and P-STAT3 (phosphorylated form of STAT3) were downregulated in reactive human astrocytes transfected with the *DLL4 siRNA* compared to reactive human astrocytes transfected with the *CTRL siRNA*. Notably, IL-6 and P-STAT3 expression level in the *DLL4 siRNA* condition was similar to the one measured in non-reactive astrocytes (Fig. 5, A-C). Under the same conditions in vitro and on spinal cord sections from *Dll4*^{ACKO}C mice and control littermates, we then demonstrated that IL-6 signal was co-localized with GFAP signal in reactive astrocytes (Fig. 5, D-E) (Supplemental Fig. 2, C) and that IL-6 expression level was downregulated following *Dll4* knockdown both in vitro and in vivo (Fig. 5, D-G) (Supplemental Fig. 2, C). To clearly establish the link between IL-6 and P-STAT3, we then measured the phosphorylation of STAT3 in vitro, in human reactive astrocytes treated with Tocilizumab, a humanized monoclonal antibody targeting IL-6 receptors, or IgG. We showed that P-STAT3 is downregulated after Tocilizumab treatment compared to IgG with an expression level

similar to the one of non-reactive astrocytes (Fig. 5, H-I). Importantly, DLL4 expression level was stable in both IgG and Tocilizumab treated reactive astrocytes, highlighting that IL-6-STAT3 interaction happened downstream of DLL4 during astrocyte reactivity (Fig. 5, H, J).

Here we showed that, following the direct upregulation of *IL-6* transcription by NICD in reactive astrocytes, IL-6 protein expression is strongly increased and leads to the phosphorylation of STAT3, an already established marker of astrocyte reactivity via its interaction with the kinase JAK.

Mice with astrocyte *Dll4* inactivation display reduced blood-brain barrier disruption, which is associated with decreases in VEGFA and TYMP secretion, protecting the parenchyma from inflammatory infiltrate in a model of multiple sclerosis and in a model of acute neuroinflammation

We compared the impact of *Dll4* blockade in astrocytes on plasma protein and inflammatory cell infiltration in the parenchyma by measuring IgG, CD4 and CD45+ lymphocyte infiltration and IBA1 expression level in vivo, on spinal cord sections from EAE induced *Dll4*^{ACKO}P and *Dll4*^{ACKO}C mice versus control littermates (Fig. 6, A-D) (Supplemental Fig. 3, A-H). We found that astrocyte *Dll4* deficient mice induced with EAE displayed less parenchymal inflammatory infiltration than control littermates (Fig. 6, A-D) (Supplemental Fig. 3, A-H). We previously reported that reactive astrocytes express pro-permeability factors, VEGFA and TYMP, which drive blood-brain barrier permeability in EAE [7]. We therefore tested whether astrocyte DLL4 signaling regulates VEGFA and TYMP expression in vitro in *DLL4 siRNA* treated reactive astrocytes and in vivo in EAE induced *Dll4*^{ACKO}P and *Dll4*^{ACKO}C mice. We found that VEGFA and TYMP were downregulated in IL-1 β induced reactive astrocytes transfected with *DLL4 siRNA* when compared to IL-1 β induced reactive astrocytes transfected with *CTRL siRNA* (Fig. 6, E-H). Moreover we showed that TYMP expression level was highly correlated to




Fig. 4 DLL4-NOTCH1 signaling in reactive astrocytes promotes IL-6 transcription via a direct interaction with NICD. **(A)** *Notch1^{ACKO}* mice and control mice induced with EAE were scored daily according to a widely-used 5-point scale (EAE scoring: 1 limp tail; 2 limp tail and weakness of hind limb; 3 limp tail and complete paralysis of hind legs; 4 limp tail, complete hind leg and partial front leg paralysis). Statistical significance was determined by using a 2 ways Anova test followed by the Holm-Sidak's multiple comparisons test, (*: $p \leq 0.05$; **: $p \leq 0.01$; ***: $p \leq 0.001$ ****: $p \leq 0.0001$). (*Notch1^{ACKO}* $n = 15$, WT $n = 16$). **(B)** NA were cultured until confluence and treated with IL-1 β 10ng/mL for 24 h. A Chromatin Immuno-Precipitation (ChIP) was then performed on NA lysates using NICD antibody versus IgG controls to pull-down. *IL-6* DNA expression level was then quantified by PCR. **(C-G)** NA were cultured until 70% confluence. They were then transduced with an empty lentivirus ($6.21 \cdot 10^8$ PFU/mL) versus a *DLL4*-expressing lentivirus ($4.14 \cdot 10^8$ PFU/mL) and harvested 24 h post transduction ($n = 11$). **(C)** *HES1*, **(D)** *HEY1*, **(E)** *HEY2*, **(F)** *IL-6* and **(G)** *DLL4* expression were quantified by qRT-PCR. β -*ACTIN* was used as a reference. Statistical significance was determined by using a Mann-Whitney U test

astrocyte reactivity threshold as it followed the same pattern as GFAP signal intensity (Fig. 6, H, J-K). We then confirmed these results in vivo, finding down-regulation of astrocyte VEGFA and TYMP signals on spinal cord sections from EAE induced *Dll4^{ACKO}* and *Dll4^{ACKO}* mice when compared to control littermates (Fig. 6, I, L-M) (Supplemental Fig. 3, I-K).

Altogether, these results suggest that, under neuro-inflammatory condition, astrocyte *Dll4* knockdown leads to decreased astrocyte reactivity and is associated with reduced levels of VEGFA and TYMP, protecting against blood-brain barrier breakdown and parenchymal inflammatory infiltrate.

To further support whether astrocyte *DLL4* participates to inflammatory lesion pathogenesis by controlling astrocyte reactivity, we decided to verify the results we obtained in the EAE mouse model, in a model of acute neuroinflammatory lesion. Initially, we compared responses of *Dll4^{ACKO}* mice and littermate controls to cortical injection of AdIL-1 β , measuring the area of neuronal cell death (NEUN loss) in lesions at 7 dpi (days post injection) (Supplemental Fig. 4, A, F). We then measured astrocyte reactivity (VIM and GFAP signal intensity) and associated IL-6 and TYMP expression in lesions at 7 dpi (Supplemental Fig. 4, B-C, G-J). Finally, the maximal area of inflammatory




Fig. 5 (See legend on next page.)

(See figure on previous page.)

Fig. 5 Astrocyte-specific *Dll4* inactivation induces downregulation of astrocyte reactivity through the downregulation of the IL-6-STAT3 pathway. **(A-C)** NA were cultured until 70% confluence and transfected with a *CONTROL* siRNA (20 μ M) versus a *DLL4* siRNA (20 μ M), starved for 12 h and treated with 1X PBS versus IL-1 β 10ng/mL for 12 h. **(A-B)** IL-6 ($n=8$) and **(A, C)** P-STAT3 ($n=6$) expression were quantified by western blot (WB). β -ACTIN (ACTB) and STAT3 total were used as references. **(D)** NA were cultured on Lab-Tek[®] until 70% of confluence. They were then treated as above. GFAP (in green) and IL-6 (in red) localizations were evaluated by immuno-fluorescent staining. Nuclei were stained with DAPI (in blue). **(E)** Spinal cord from control tissues or EAE lesions (18 days post induction) from *Dll4*^{ACKO}P mice, *Dll4*^{ACKO}C mice and littermate controls were harvested. *Dll4*^{ACKO}P, *Dll4*^{ACKO}C and control tissues were immunostained with anti-GFAP (in green) and anti-IL-6 (in red) antibodies. Nuclei were stained with DAPI (in blue). *Dll4*^{ACKO}C and control tissues are shown. **(F-G)** IL-6 positive areas were quantified **(F)** in reactive NA ($n=8$) and **(G)** in spinal cord lesions (3 lesions per tissue) (*Dll4*^{ACKO}P mice $n=6$, WT $n=5$) (*Dll4*^{ACKO}C mice $n=7$, WT $n=6$). **(H-J)** NA were cultured until 70% confluence. They were then starved for 12 h and treated with 1X PBS versus IL-1 β 10ng/mL with IgG or an anti-IL-6 receptor antibody Tocilizumab (1 μ g/mL) for 24 h. **(H-I)** P-STAT3 ($n=5-6$) and **(H, J)** DLL4 were quantified by western blot ($n=5-6$). STAT3 total and ACTB were used as references. Statistical significance was determined by using a Mann-Whitney U test or Kruskal Wallis test followed by the Dunn's multiple comparison test

infiltration into the CNS in term of parenchymal entry of serum proteins, notably FGB (fibrinogen), and CD4⁺ T helper lymphocytes was assessed in lesions at 7 dpi (Supplemental Fig. 4, D-E, K-L). Importantly, these studies demonstrated that lesion formation in *Dll4*^{ACKO}P mice was strongly decreased compared to littermate controls. Confirming efficacy and specificity of inactivation, AdIL-1 β -induced lesions in *Dll4*^{ACKO}P mice showed lower levels of DLL4 (Supplemental Fig. 1, K). Lesion size in *Dll4*^{ACKO}P mice, as measured by neuronal cell death or loss of NEUN immunoreactivity, was much narrower than in controls at 7 dpi (Supplemental Fig. 4, A, F). Moreover, GFAP and VIM, two markers of astrocyte reactivity were strongly downregulated in *Dll4*^{ACKO}P mice compared to controls and were associated with a decreased expression of astrocyte reactivity marker IL-6 and pro-permeability marker TYMP (Supplemental Fig. 4, B-C, G-J). There were also large decreases in the areas of cortical FGB and CD4⁺ T helper lymphocytes infiltration seen in AdIL-1 β lesions in *Dll4*^{ACKO}P mice at 7 dpi (Supplemental Fig. 4, D-E, K-L).

We concluded that astrocyte DLL4 upregulation during acute neuroinflammation leads to astrocyte reactivity in the lesion area and upregulation of the pro-inflammatory cytokine IL-6 and pro-permeability factor TYMP by reactive astrocytes. Lesion size is more severe in presence of astrocytic DLL4 and associated with a stronger inflammatory infiltrate of fibrinogen and immune cells into the parenchyma. Altogether our findings in both cortical AdIL-1 β lesions and spinal cord EAE support a global role for astrocytic DLL4 in driving astrocyte reactivity and neuroinflammatory lesion pathogenesis.

Blockade of DLL4 protects against blood-brain barrier opening and paralysis in EAE

To test the therapeutic potential of exogenous DLL4 blockade during EAE, we designed experiments to test the effects of an anti-DLL4 antibody. To probe for possible off-target effects of DLL4 blockade on the vascular endothelium, we first tested the EAE phenotype in

a transgenic mouse with conditional endothelial *Dll4* inactivation as DLL4 contributes to the regulation of angiogenesis via DLL4-mediated NOTCH1 signaling in endothelium, a key pathway for vascular development [35]. Therefore, we induced EAE in 10 weeks old *Cadherin5-Cre*^{ERT2}, *Dll4*^{Flox/Flox} mice and corresponding littermate controls and found that *Dll4* endothelial specific downregulation had no impact on EAE disease severity (Supplemental Fig. 5, A), associated peak (Supplemental Fig. 5, B) and average score during time of disability (Supplemental Fig. 5, C). Moreover, in C57BL/6 spinal cord EAE lesions, we showed that DLL4 is not expressed by SMA+ mural cells (Supplemental Fig. 5, D-E). Altogether, these data suggest that exogenous DLL4 blockade with an anti-DLL4 antibody would have minimal effects on the vascular endothelium impacting the course or neuropathology of EAE.

We then compared the impact of DLL4 blockade on disease severity in EAE (Fig. 7). We sensitized 8 weeks old C57BL/6 mice (9 per group) and, beginning on day 8 post sensitization (just at the beginning of the onset of the disease), treated them every three days for eleven days with the inVivoMab anti-mouse DLL4 antibody (500 μ g/mouse/d). The inVivoMab polyclonal Armenian hamster IgG (500 μ g/mouse/d) was injected to the mice in the control group. Neurological signs and pathology were evaluated from day 1 to day 25 post sensitization.

Onset of the disease occurred at day 10 post-sensitization, and ascending paralysis was first observed 24 h later, with severity in controls (polyclonal Armenian hamster IgG-treated mice) increasing until day 19, when neurologic deficit reached a plateau at a mean score of 3.3, indicating severe disease with complete hindlimb paralysis (Fig. 7, A). Signs in anti-mouse DLL4 antibody-treated mice were much milder, peaking at day 16 at a mean score of just 2.4, indicative of a limp tail with moderate hindlimb weakness (Fig. 7, A). Comparison of peak clinical severity in each individual was different between the anti-mouse DLL4 antibody and the polyclonal Armenian hamster IgG-treated regimens (Fig. 7, B). For anti-mouse DLL4 antibody,

differences in disease severity were highly significant compared with polyclonal Armenian hamster IgG-treated controls (Fig. 7, C). Almost all controls (89%) but only 33% of anti-mouse DLL4 antibody-treated mice displayed complete hindlimb paralysis or worse (score ≥ 3) (Fig. 7, A-C). No mortality at all was encountered in all cohorts.

These improvements in clinical disease observed with the anti-mouse DLL4 antibody were associated with reduced tissue damage, in terms of decreased demyelination (Fig. 7, D, H). They were also associated with reduced blood–brain barrier breakdown, plasmatic protein and inflammatory cell infiltration (Fig. 7, E-F, J-L) and astrocyte reactivity (Fig. 7, G-H, M-N). No difference was observed in term of microglial activation (Fig. 7, D, K). Downregulation of astrocyte reactivity in the anti-mouse DLL4 antibody group was associated to a decreased expression of the pro-inflammatory cytokine IL-6 and of the pro-permeability factors TYMP and VEGFA (Fig. 7, G-H, O-P).

Collectively, the results of these therapies confirm the therapeutic benefit of exogenous DLL4 blockade during EAE and support our findings that astrocyte DLL4 promotes astrocyte reactivity during neuroinflammation, which contributes to TYMP and VEGFA astrocytic secretion leading to blood-brain barrier permeability.

Methods

Human tissues

Cortical sections from multiple sclerosis patients (active lesions) and healthy controls (frontal cortex) were obtained from the Neuro-CEB bio bank (<https://www.neuroceb.org/fr>). The sections were 30 μm thick and obtained from fresh frozen samples.

Mice

The *Glast-Cre^{ERT2}* mice, *Aldh1L1-Cre^{ERT2}* mice, *Cdh5-Cre^{ERT2}* mice, *Dll4 Floxed (Dll4^{Flox})* mice, *Notch1 Floxed (Notch1^{Flox})* and C57BL/6 mice were purchased from Jackson Laboratories (Bar Harbor, ME, USA).

The Cre recombinase in *Glast-Cre^{ERT2}* mice, *Aldh1L1-Cre^{ERT2}* mice and *Cdh5-Cre^{ERT2}* mice was activated by intraperitoneal injection of 1 mg tamoxifen (Sigma Aldrich, St. Louis, MO, USA) for 5 consecutive days at 8 weeks of age. Mice were phenotyped 2 weeks later. Successful and specific activation of the Cre recombinase has been verified by measuring recombination efficacy in *Glast-Cre^{ERT2};Rosa26^{mTmG}* mice, *Aldh1L1-Cre^{ERT2};Rosa26^{mTmG}*, and *Cdh5-Cre^{ERT2}; Rosa26^{mTmG}* mice (Supplemental Fig. 1, A-H) [4].

Neurovascular fraction enrichment from mouse CNS

Mouse was sacrificed by cervical dislocation. Spinal cord was then harvested and transferred in a potter containing 2 mL of buffer A (HBSS 1X w/o phenol red (Gibco, Waltham, MA, USA), 10 mM HEPES (Gibco, Waltham, MA, USA) and 0,1% BSA (Sigma Aldrich, St. Louis, MO, USA) and the tissue was pounded to obtain an homogenate which was collected in a 15 mL tube. The potter was rinsed with 1 mL of buffer A which was added to the 2 mL homogenate. Cold 30% dextran solution was then added to the tube (V: V) to obtain a 15% dextran working solution centrifuged for 25 min at 3000 g, 4 °C without brakes. After centrifugation, the pellet (neurovascular components and red cells) was collected and the supernatant (dextran solution and neural components) was centrifuged again to get the residual vessels. Neurovascular components were then pooled and re-suspended in 4 mL of buffer B (HBSS 1X Ca²⁺/ Mg²⁺ free with phenol red (Gibco, Waltham, MA, USA), 10 mM HEPES (Gibco, Waltham, MA, USA) and 0,1% BSA (Sigma Aldrich, St. Louis, MO, USA)).

Neurovascular fraction enrichment for qRT-PCR

After centrifugation of the cell suspension, the pellet was washed 3 times with the buffer B and filtered through a 100 μm nylon mesh (Millipore Corporation, Burlington, MA, USA). The nylon mesh was washed with 7 mL of buffer B to collect the retained enriched neurovascular fractions. The suspension was then centrifuged for 10 min at 1000 g and the pellet suspended in 300 μL of RIPA lysis buffer for western blot analysis or 1000 μL of Tri-Reagent (MRC, Cincinnati, OH, USA) for qRT-PCR analysis.

RNA sequencing

RNA was isolated using Tri Reagent® as instructed by the manufacturer (Molecular Research Center Inc). Each sample was obtained from a single mouse. mRNA library preparation was performed based on manufacturer's recommendations (KAPA mRNA Hyper-Prep Kit [ROCHE]). Pooled library preparations were sequenced on NextSeq® 500 whole genome sequencing (Illumina®), corresponding to 2 \times 30 million reads per sample after demultiplexing.

Quality of raw data was evaluated with FastQC [36]. Poor-quality sequences were trimmed or removed with Trimmomatic [37] software to retain only good quality paired reads. Star v2.5.3a [38] was used to align reads on mm 10 reference genome using standard options. Quantification of gene and isoform abundances was done using RNA-Seq by Expectation-Maximization (RSEM) 1.2.28, prior to normalization using the edgeR Bioconductor software package³⁹. Finally, differential




Fig. 6 (See legend on next page.)

(See figure on previous page.)

Fig. 6 *Dll4*^{ACKO} mice display reduced blood-brain barrier disruption in EAE, protecting against inflammatory infiltrate. **(A-D)** Spinal cord EAE lesions from *Dll4*^{ACKO} mice, *Dll4*^{ACKO} mice and littermate controls were harvested at 18 days post induction. **(A-B)** *Dll4*^{ACKO} and control lesions were immuno-stained with **(A)** anti IgG (in green) and anti-PODXL (in red) antibodies and **(B)** anti CD4 (in green) and anti LAM (in red) antibodies. Nuclei were stained with DAPI (in blue). *Dll4*^{ACKO} and control tissues are shown. **(A, C)** IgG and **(B, D)** CD4 positive areas were quantified (3 lesions/tissue) (*Dll4*^{ACKO} mice *n* = 6, WT *n* = 5) (*Dll4*^{ACKO} mice *n* = 7, WT *n* = 7). **(E-G)** NA were cultured, transfected with a CONTROL siRNA (20 μM) versus a *DLL4* siRNA (20 μM), starved for 12 h and treated with 1X PBS versus IL-1β 10ng/mL for 12 h. **(E-F)** TYMP and **(E, G)** VEGFA expression were quantified by WB. β-ACTIN (ACTB) was used as a reference. (*n* = 6) **(H)** NA were cultured on Lab-Tek® and treated as above. GFAP (in green) and TYMP (in red) localizations were evaluated by immuno-fluorescent staining. Nuclei were stained with DAPI (in blue). **(I)** Spinal cord EAE lesions from *Dll4*^{ACKO} mice, *Dll4*^{ACKO} mice and littermate controls were harvested at 18 days post induction. *Dll4*^{ACKO} and control lesions were immuno-stained with anti-GFAP (in green) and anti-VEGFA (in red) or anti-TYMP (in red) antibodies. Nuclei were stained with DAPI (in blue). Representative GFAP/VEGFA staining of *Dll4*^{ACKO} and control lesions is shown. **(J)** GFAP and **(K)** TYMP positive areas were quantified in reactive NA in cultures (*n* = 8) and **(L)** TYMP and **(M)** VEGFA positive areas were quantified in spinal cord lesions (3 lesions/tissue) (*Dll4*^{ACKO} mice *n* = 6, WT *n* = 6) (*Dll4*^{ACKO} mice *n* = 7, WT *n* = 6). Statistical significance was determined by using a Mann-Whitney U test or Kruskal Wallis test followed by the Dunn's multiple comparison test

analysis was conducted with the generalized linear model (GLM) framework likelihood ratio test from edgeR. Multiple hypothesis-adjusted *p*-values were calculated using the Benjamini-Hochberg procedure to control for the false discovery rate (FDR). The fragments per kilobase per million mapped reads (FPKM) values of all transcripts of which expression was significantly different between MOG_{35–55} EAE-sensitized *Dll4*^{ACKO} mice and littermate controls is provided in the additional file 2.

Cell culture

Human Normal Astrocytes (NA) (ScienCell, Carlsbad, California) were cultured in astrocyte medium (AM) (ScienCell, Carlsbad, California). Cell from passage 2 to passage 4 were used. Before any treatment, cells were serum starved in DMEM 1 g/L glucose, Mg⁺, Ca²⁺ (Gibco, Waltham, MA, USA) without serum for 12–24 h depending on the experiment.

Transfection/transduction

ON-TARGET plus SMART Pool Human non-targeting (20 μM) and Human *DLL4* siRNA (20 μM) were purchased from Dharmacon (Colorado, USA). Cells were transfected using JetPRIME™ transfection reagent (Polyplus Transfection) according to the manufacturer's instructions. More precisely, 500 000 astrocytes were seeded in 3.8 cm² cell culture wells. Transfection was done at day +1 with 1.8 μL of each siRNA and 4 μL JetPRIME per well. Cells were starved in DMEM 1 g/L glucose, Mg⁺, Ca²⁺ (Gibco, Waltham, MA, USA) at day +2, treated with PBS or IL-1β (10 ng/mL) at day +3 and RNA or protein samples harvested at day +4.

The human *DLL4* plasmid vector was obtained from the Theodor-Boveri-Institute, (Physiological Chemistry I, Biocenter of the University of Wurzburg) and the lentiviral plasmid was then produced and amplified in our lab. The empty lentiviral vector (*pRRlsin.MND.MCS.WPRE (lentiMND14)*) was produced and amplified in our lab. 500 000 astrocytes were seeded in 3.8 cm² cell culture wells and incubated for 18 h before infection. Lentiviral supernatant was added with

multiplicity of infection (MOI) at 10. After 8 h, the lentiviral supernatant was replaced with fresh complete cell culture medium and the cells were incubated for 24 h before harvesting RNA samples.

Cytokines/growth factors/chemicals


Human IL-1β was purchased from PeproTech (Rocky Hills, NJ, USA) and used at 10 ng/mL. U0126, a cell permeable inhibitor of MAPK (ERK 1/2) was purchased from Cell Signaling (Danvers, MA, USA) and used at 10 μM. The humanized anti-IL-6 receptor antibody Tocilizumab was used at 1 μg/mL.

Antibodies

Anti-CDH5 (Goat), anti-DLL4 (goat), anti-IL-6 (goat), anti-PODXL (goat), anti-SOX9 (goat) and anti-TYMP (goat) were from R&D systems (Minneapolis, MN, USA). Anti-FGB (rabbit) was from Dako (Carpinteria, CA, USA). Anti-human-LCN2 (mouse), anti-MBP (rat), anti-SMA (rabbit) and anti-VEGFA (Rabbit) were from Abcam (Cambridge, MA, USA). Anti-CD4 (rat) and anti-GFAP (rat and rabbit) were from Thermo Fisher Scientific (Waltham, MA, USA). Anti-RNA binding fox-1 homolog 3 (NEUN) (rabbit) was from Millipore (Billerica, MA, USA). Anti-human-DLL4 (Rabbit) and anti-LAM (rabbit) were from Sigma Aldrich (St. Louis, MO, USA). Anti ACTB (rabbit), anti-CASP3 (rabbit) and Cleaved CASP3 (rabbit), anti-cleaved NOTCH1 (NICD) (rabbit), anti-DLL4 (rabbit), anti-human-JAG1 (rabbit) and anti-VIM (rabbit) were from cell signaling (Danvers, MA, USA). Anti-human-IL-6 (rabbit) was from Proteintech (Rosemont, IL, USA). Anti-human-STAT3 (mouse) and anti-human-P-STAT3 Tyr705 (rabbit) were from Ozyme (Saint-Cyr-l'École, France). Anti-IBA1 (rabbit) was from Fujifilm Wako (Osaka, Japan). Anti-GFP (Goat) was from Novus Biologicals (Minneapolis, MN, USA).

Chromatin immunoprecipitation

Chromatin immune-precipitation (ChIP) assay was performed with human NAs treated with IL-1β for 12 h. Proteins were crosslinked to DNA by adding

**Fig. 7** (See legend on next page.)

(See figure on previous page.)

Fig. 7 Blockade of DLL4 protects against blood-brain barrier opening and paralysis in EAE. **(A)** Mean clinical scores are shown from mice (10-week-old female *C57BL/6*, 9 per group) sensitized with EAE MOG₃₅₋₅₅, then from onset of disease (8 days post-induction) treated every 3 days for 11 days (red arrows) with an inVivoMab anti-mouse DLL4 antibody (500 µg/mouse/d) or an inVivoMab polyclonal Armenian hamster IgG (500 µg/mouse/d) in the control group. Neurological deficit was scored (from day 1 to day 25 post sensitization) daily for each animal according to a widely-used 5-point scale (EAE scoring: 1 limp tail; 2 limp tail and weakness of hind limb; 3 limp tail and complete paralysis of hind legs; 4 limp tail, complete hind leg and partial front leg paralysis), Statistical analysis was determined by using a 2 ways Anova test followed by the Holm-Sidak's multiple comparisons test (*: $p \leq 0.05$; **: $p \leq 0.01$; ***: $p \leq 0.001$ ****: $p \leq 0.0001$). **(B)** For each group of mice, EAE peak score and **(C)** EAE average score during time of disability was quantified other the course of the disease. **(D-I)** Cortical lesions were immuno-stained with **(D)** anti MBP (in green) and anti-IBA1 (in red) antibodies, **(E)** anti-CD4 (in green) and anti-CDH5 (in red) antibodies, **(F)** anti-IgG (in grey) and anti-CDH5 (in red) antibodies, **(G)** anti-GFAP (in green) and anti-IL-6 (in red) antibodies, **(H)** anti-CD31 (in green), anti-VIM (in red) and anti-TYMP (in grey) antibodies and **(I)** anti-VEGFA (in green) and anti-GFAP (in red) antibodies. **(D-I)** Nuclei were stained with DAPI (in blue). **(J)** MBP, **(K)** CD4, **(L)** IBA1, **(M)** IgG, **(N)** VIM+/CD31-, **(O)** GFAP, **(P)** IL-6, **(Q)** TYMP and **(R)** VEGFA positive areas were quantified in spinal cord lesions (3 lesions per tissue). (inVivoMab anti-mouse DLL4 antibody group $n = 7$, inVivoMab polyclonal Armenian hamster IgG $n = 6$). Statistical significance was determined by using a Mann-Whitney U test

formaldehyde to the culture media to a final concentration of 1% and incubating for 10 min at 37 °C.

Fixed cells were rinsed twice with ice cold PBD containing AEBSF 1/1000 v/v, leupeptine 1/1000 v/v and aprotinine 1/1000 v/v. Cells (1 million) were lysed in 1.000µL of SDS buffer (SDS 1% v/v, EDTA 10mM, Tris-HCl 50mM pH8, AEBSF 1/1000 v/v, leupeptine 1/1000 v/v, aprotinine 1/1000 v/v). Lysate was sonicated on ice 20 times for 10 s to obtain DNA fragments with an average size of 500 bp. The chromatin solution was diluted in dilution buffer to a final volume of 2mL and incubated 30 min at +4 °C with 30 µg of protein G sepharose and 5 µg of salmon sperm DNA. After centrifugation, the supernatant was incubated overnight at +4 °C with 10 µl of anti-human NICD antibody or non-specific IgG. After being washed twice in PBS, 30 µg of G protein beads were blocked with 5 µg of salmon sperm DNA added to each sample and incubated one hour at +4 °C. Immuno-precipitated samples were centrifuged and washed once in low salt wash buffer, once in high salt wash buffer, once in LiCl wash buffer. Samples were then washed twice in Tris-EDTA. Elution of immune-precipitated chromatin was performed by adding 250µL of elution buffer and incubation was performed at room temperature for 15 min, and repeated once. To reverse DNA crosslinking, the eluate was incubated for 4 h at 65 °C after adding 20µL of NaCl 5 M. Samples were then incubated 1 h at 65 °C with 2µL of proteinase K, 10µL of EDTA 0,5 M and 20µL of TE 1 M pH 6.5 for protein removal. DNA was then purified using phenol/chloroform extraction.

Quantitative RT-PCR

RNA was isolated using Tri Reagent® (Molecular Research Center Inc) as instructed by the manufacturer, from 3×10^5 cells or from isolated mouse enriched neurovascular fractions. For quantitative RT-PCR analyses, total RNA was reverse transcribed with M-MLV reverse transcriptase (Promega, Madison, WI, USA) and amplification was performed on a DNA Engine Opticon®2 (MJ Research Inc, St Bruno, Canada) using B-R SYBER® Green SuperMix (Quanta

Biosciences, Beverly, MA, USA). Primer sequences are reported in Table 1.

The relative expression of each mRNA was calculated by the comparative threshold cycle method and normalized to β -actin mRNA expression.

Western blots

Protein expression was evaluated by SDS-PAGE. Protein loading quantity was controlled using the rabbit monoclonal anti-ACTB antibody (cell signaling, Danvers, MA, USA) or the mouse monoclonal anti-TUBULIN antibody (Sigma-Aldrich, Saint Louis, MI, USA). Secondary antibodies were from Invitrogen. The signal was then revealed by using an Odyssey Infrared imager (LI-COR, Lincoln, NE, USA). For quantification, the mean pixel density of each band was measured using Image J software (NIH, Bethesda, MD, USA) and data were standardized to ACTB or TUBULIN, and fold change versus control calculated.

Stereotactic injection

10 weeks old *Dll4^{ACKO}* mice and littermate *controls* (6 mice per condition) were anaesthetized using isoflurane (3% induction and 1% maintenance) (Virbac Schweiz, Glattbrugg, Germany) and placed into a stereotactic frame (Stoelting Co., IL, USA). To prevent eye dryness, an ophthalmic ointment was applied at the ocular surface to maintain eye hydration during the time of surgery. The skull was shaved and the skin incised on 1 cm to expose the skull cap. Then, a hole was drilled into the skull, using a pneumatic station S001+TD783 Bien Air, until reaching the dura mater. AdIL-1 β (10^7 PFU) was then delivered into the frontal cortex at coordinates of 1 µm posterior to bregma, 2 µm left of the midline and 1.5 µm below the surface of the cortex.

Mice received a subcutaneous injection of buprenorphine (0,05 mg/kg) (Ceva santé animale, Libourne, France) 30 min before surgery and again 8 h post-surgery to assure a constant analgesia during the procedure and postoperatively. Mice were sacrificed by pentobarbital (Richter Pharma, Wels, Austria)

Table 1 List of primers used for reverse transcription (RT) quantitative polymer chain reaction (qPCR)

<i>mDll4</i>	F	5'-TGGCAATGTCTCCACGCCGG-3'
	R	5'-TGTTGCCAAATCTTACCCACAGCA-3'
<i>mHey1</i>	F	5'-TCCATGTCCCAACGACATC-3'
	R	5'-GCAGTGTGCAGCATTTTCAG-3'
<i>mJag1</i>	F	5'-AGTGCATGTGTCCCGGTGGC-3'
	R	5'-CCGTCCACACAGGTCCCGCTA-3'
<i>mVegfC</i>	F	5'-TTTAAGGAAGCACTTCTGTGTGT-3'
	R	5'-GTAAAAACAACTTTTCCCTAATTC-3'
<i>mβ-actin</i>	F	5'-GATCAAGATCATTGCTCCTCTCG-3'
	R	5'-AGGGTGTAACACGCAGCTCA-3'
<i>hDLL4</i>	F	5'-CCTTCGCTGTCCGGACGACA-3'
	R	5'-TCTGACCCACAGCTAGGGAGCC-3'
<i>hHES1</i>	F	5'-CACCTCCGGAACCTGCAGCG-3'
	R	5'-CAGTTGGCCAGGTGGCCGAG-3'
<i>hHEY1</i>	F	5'-TGAGAAGGCTGGTACCCAGTGCT-3'
	R	5'-TCCATAGCAAGGGCGTGCCG-3'
<i>hHEY2</i>	F	5'-AGATGCTTCAGGCAACAGGGGGT-3'
	R	5'-GGAGCTCAGGTACCCGCGCA-3'
<i>hIL-6</i>	F	5'-TCTTGGGACTGATGCTGGTGAC-3'
	R	5'-TGAAGGACTCTGGCTTTGTCTTTC-3'
<i>hTYMP</i>	F	5'-GGAAGTTCCGCGTGCC-3'
	R	5'-GACCGTAGGGTTCAGGGTTC-3'
<i>hβ-ACTIN</i>	F	5'-CACACAGGGGAGGTGATAGC-3'
	R	5'-GACCAAAAGCCTTCATACATCTCA-3'

F forward, R reverse

β-actin was used as the household gene

overdose at 7 days post injection (dpi). For histological assessment, the brain of each animal was harvested.

Experimental autoimmune encephalomyelitis (EAE)

10 week old female mice were immunized by subcutaneous injection of 300 µg myelin oligodendrocyte glycoprotein-35-55 (MOG₃₅₋₅₅) (Hooke laboratories, Lawrence, MA, USA) in 200 µl Freund's Adjuvant containing 300 µg/mL mycobacterium tuberculosis H37Ra (Hooke laboratories, Lawrence, MA, USA) in the dorsum. Mice were administered with 500 ng pertussis toxin (PTX) *intra-peritoneously* on day of sensitization and 1 day later (Hooke laboratories). The emulsion provides antigen which initiates expansion and differentiation of MOG-specific autoimmune T cells. PTX enhances EAE development by providing additional adjuvant. EAE will develop in mice 7–14 days after immunization (Day 0): animals which develop EAE will become paralyzed. Disease was scored (0, no symptoms; 1, floppy tail; 2, hind limb weakness (paraparesis); 3, hind limb paralysis (paraplegia); 4, fore- and hind limb paralysis; 5, death) [39] from day 7 post immunization until day 28 post immunization. At Day 28, all the animals were euthanized by pentobarbital (Richter Pharma, Wels, Austria) overdose. For histological assessment, cervical, lumbar and

dorsal sections of each animal spinal cord, as well as the spleen, were harvested.

Therapies

inVivoMab polyclonal Armenian hamster IgG (500 µg/mouse/d) was used as control group therapy. *InVivoMab* anti-mouse DLL4 antibody (500 µg/mouse/d) was used as experimental group therapy. Intra-peritoneal injection of each therapy was injected (9 mice per therapy) at day 8, day 12, day 15 and day 18 post EAE immunization.

Immunohistochemistry

Prior to tissue collection and staining, mice were transcardially perfused with PBS (10mL) followed by 10% Formalin (10mL) to remove intravascular plasma proteins. Brain and spinal cord samples were either fixed in 10% formalin for 3 h, incubated in 30% sucrose overnight, OCT embedded and cut into 9 µm thick sections or directly OCT embedded and cut into 9 µm thick sections. Cultured cells were fixed with 10% formalin for 10 min. Human frozen sections were used directly without any prior treatment. Concerning the fixed sections, for IL-6, prior to blocking, sections were soaked in Citrate (pH 7.5; 100 °C). For TYMP, prior to blocking, sections were soaked in EDTA (pH 6.0; 100 °C). For CD4, sections were treated with 0.5 mg/mL protease XIV (Sigma Aldrich, St. Louis, MO, USA) at 37 °C for 5 min. Primary antibodies were used at 1:100 except DLL4 (1:50), FGB (1:500) and LAM (1:1,000). Samples were examined using a Zeiss Microsystems confocal microscope (Oberkochen, Germany), and stacks were collected with *z* of 1 µm.

For immunofluorescence analyzes, primary antibodies were resolved with Alexa Fluor®-conjugated secondary polyclonal antibodies (Invitrogen, Carlsbad, CA, USA) and nuclei were counterstained with DAPI (1:5000) (Invitrogen, Carlsbad, CA, USA). For all immunofluorescence analyses, negative controls using secondary antibodies only were done to check for antibody specificity.

Morphometric analysis

Morphometric analyses were carried out using NIH ImageJ software (NIH, Bethesda, MD, USA).

GFAP and IBA1 signals were counted in Z series stacks at 20× magnifications by a blinded observer using ImageJ software win64 in brain or lumbar, thoracic and cervical spinal cord sections from healthy or EAE induced animals, on at least 3 fields containing EAE-induced white matter lesions, at 20× magnifications per animal. To quantify GFAP or IBA1 levels, the GFAP+or IBA1+area in each section was measured

in Z series stacks at 20× magnifications using ImageJ software win64, and expressed as absolute area.

DLL4, IL-6, TYMP and VEGFA signals were counted in Z series stacks at 20× magnifications by a blinded observer using ImageJ software win64 in human normal astrocytes in culture, brain or lumbar, thoracic and cervical spinal cord sections from healthy or EAE induced animals on at least 3 fields containing EAE-induced white matter lesions, at 20× magnifications per animal. To quantify DLL4, IL-6, TYMP or VEGFA levels, the DLL4+, IL-6+, TYMP+ or VEGFA+ area co-localized with the GFAP+ area in each section was measured in Z series stacks at 20× magnifications using ImageJ software win64, and expressed as absolute area.

MBP signal was counted in Z series stacks at 20× magnifications by a blinded observer using ImageJ software win64 in lumbar, thoracic and cervical spinal cord sections from healthy or EAE induced animals, on at least 3 fields at 20× magnifications per animal. To quantify white matter myelination, the MBP+ area in each section in the white matter was measured in Z series stacks at 20× magnification using ImageJ software win64, and expressed as absolute area.

VIM signal was counted in Z series stacks at 40× magnifications by a blinded observer using ImageJ software win64 in brain or lumbar, thoracic and cervical spinal cord sections, on at least 3 fields containing EAE-induced white matter lesions, at 40× magnifications per animal. To quantify astrocytic VIM+ signal, the VIM+ area was measured in Z series stacks at 40× magnifications using ImageJ software win64, and the VIM+ signal co-localized with the PODXL+ signal has been subtracted in each section. VIM+ area is expressed as absolute area.

Blood-brain barrier permeability was evaluated by measuring plasmatic protein extravasation. Brain and spinal cord sections were immunostained for the expression of IgG. For each brain or spinal cord section, IgG+ areas were quantified on at least 3 fields containing EAE-induced white matter lesions under 20× magnifications.

Leukocyte densities were evaluated in sections stained for the expression of CD45+ leukocyte and CD4+ T lymphocyte populations. For each brain or spinal cord section, CD45+ and CD4+ areas were quantified on at least 3 fields containing EAE-induced white matter lesions under 20× magnifications. One section was quantified per spinal cord.

Isolation of adult mouse leukocyte and astrocyte fractions using miltenyi biotec protocols

Before harvest, the spinal cord was perfused with NaCl 0.9% solution. Spinal cord was then dissociated using

the gentleMACS Octo Dissociator by following the Multi Tissue Dissociation Kit protocol from MACS Myltenyi.

https://static.miltenyibiotec.com/asset/150655405641/document_50e3huts562f80ad9a9e59e6m?content-disposition=inline.

Then, spinal cord dissociated sample was subjected to a debris removal step before being labeled with CD45 microbeads, mouse and enriched via magnetic cell sorting on LS columns for the positive selection of leukocytes from spinal cord samples.

https://static.miltenyibiotec.com/asset/150655405641/document_nj4tl3c3at7r524gmnsfm9ut3p?content-disposition=inline.

Finally, spinal cord dissociated sample, depleted in CD45+ cells, was labeled with Anti-ACSA-2 (ACSA-2: astrocyte cell surface antigen-2) microbeads, mouse and enriched via magnetic cell sorting on MS columns for the positive selection of astrocytes from spinal cord samples.

https://static.miltenyibiotec.com/asset/150655405641/document_n3397vmccp4fle7df8ictuu90j?content-disposition=inline.

Statistical analyses

Results are reported as mean ± SEM. Comparisons between groups were analyzed for significance with the non-parametric Mann-Whitney test, the non-parametric Kruskal Wallis test followed by the Dunn's multiple comparison test when we have more than 2 groups or a 2 ways Anova test followed by the Holm-Sidak's multiple comparisons test for the EAE scoring analysis using GraphPad Prism v8.0.2 (GraphPad Inc, San Diego, CA, USA). Differences between groups were considered significant when $p \leq 0.05$ (*: $p \leq 0.05$; **: $p \leq 0.01$; ***: $p \leq 0.001$ ****: $p \leq 0.0001$).

Differential analysis of the RNA sequencing dataset has been conducted with the glm framework likelihood ratio test from edgeR. Multiple hypothesis adjusted p -values were calculated with the Benjamini-Hochberg procedure to control FDR.

Conclusions

A complex network of intercellular signaling occurs between cells of the neurovascular unit during neuroinflammation [1, 3]. Understanding the pathways controlling reactive astrocyte reactivity and blood-brain barrier function is of considerable translational interest to the field of neuro-immunology and stroke. Here, we report for the first time, a role for juxtacrine astrocytic DLL4 mediated NOTCH1 receptor signaling as a key regulator of astrocyte reactivity and blood-brain barrier leakage in two models of CNS autoinflammatory disease.

First, we found that astrocytic DLL4 expression is upregulated during neuroinflammation, both in mice and humans, promoting astrocyte reactivity and subsequent blood-brain barrier permeability and inflammatory infiltration during pathology. We then show that the DLL4-mediated NOTCH1 juxtacrine signaling in astrocytes directly controls IL-6 transcriptional level and triggers the phosphorylation of STAT3, driving astrocyte reactivity and inducing pro-permeability factor secretion and subsequent blood-brain barrier destabilization. Finally we reveal that targeting DLL4 with exogenous blocking antibodies improves EAE symptoms in mice. Together, these data identify the DLL4-NOTCH1 axis as a key driver of astrocyte reactivity during neuroinflammation via the promotion of the IL-6-STAT3-TYMP/VEGFA signaling actors leading to the disruption of the neurovascular unit and worsening pathology (Fig. 8).

In multiple sclerosis, resident and infiltrating immune cells produce cytokines that activate astrocytes. This astrocyte reactivity leads to overexpression of DLL4 in astrocytes; DLL4 interacts with its membrane receptor NOTCH1 on the surface of a neighboring astrocyte. This leads to translocation of the intracellular active form of NOTCH1 (NICD) into the nucleus where it acts as a transcription factor to stimulate expression of the pro-inflammatory cytokine IL-6. As a result, IL-6 binds to its receptor JAK which leads to phosphorylation of STAT3, a pathway known to stimulate astrocyte reactivity. In response to astrocyte reactivity induced by the DLL4-NOTCH1 pathway and

the NICD-IL-6-JAK/STAT signaling cascade, astrocytes secrete pro-permeability factors (TYMP and VEGFA) that participate to blood-brain barrier opening and inflammatory infiltration of the parenchyma. Thus, an astrocyte reactivity amplification loop led by DLL4-NOTCH1 is established and actively participates in the pathophysiology of neuroinflammation.

The expression of DLL4 by reactive astrocytes has been acknowledged once in a model of brain injury in a paper published in 2021 [25]. Consistently, the group of Shane Liddelow in New York published reactive astrocyte genomics has shown upregulation of DLL4 in both C57BL/6 mouse A1 neurotoxic astrocytes stimulated with IL1 α , TNF and C1q for 24 h versus non-stimulated astrocytes and in human iPSC-derived astrocytes stimulated with cytokines IL1 α , TNF and C1q for 24 h versus non-stimulated astrocytes (<https://www.liddelowlab.com/gliaseq>). Data from the literature and our results demonstrate that, in the CNS, DLL4 is only expressed by endothelial cells under non-pathological conditions (<https://betsholtzlab.org/VascularSingleCells/database.html>) and by activated astrocytes under neuroinflammatory conditions (<https://www.liddelowlab.com/gliaseq>). Mural cells (Supplemental Fig. 5, D-E) microglia [40] and neurons [41] do not express DLL4.

In the present study, we unraveled for the first time the role of the DLL4-NOTCH1 axis and associated signaling pathways, in controlling reactive astrocyte reactivity in two models of CNS inflammation (acute CNS inflammation model and EAE, a model of




Fig. 8 Summary scheme of the role of DLL4-NOTCH1 signaling on astrocyte reactivity during neuroinflammation

multiple sclerosis). The next step would be to examine astrocytic DLL4 expression in other pathologies of the CNS, notably Alzheimer's disease, stroke or amyotrophic lateral sclerosis in which astrocytic NOTCH1 upregulation and subsequent blood-brain barrier permeability have already been identified as critical pathophysiological players [9–12]. This could implicate DLL4-NOTCH1 mediated reactive astrocyte reactivity as a more generalized mechanism in other chronic diseases of the CNS.

Like other neuroimmune factors, astrocytes are a primary source of IL-6 in the CNS [42–45] and IL-6 signaling has been shown to activate downstream pathways including JAK/STAT in various conditions including neuroinflammatory disorders. In 2021, an international consortium of scientists working on astrocytes defined a “reactive astrocyte” nomenclature; they identified STAT3-mediated transcriptional programs as one of the pathways inducing astrocyte reactivity [28]. Here we demonstrated for the first time that DLL4-mediated NOTCH1 juxtacrine signaling directly controls IL-6 transcriptional level in reactive astrocytes under inflammatory condition. Based on our results and the literature, we therefore assume that DLL4-NOTCH1 axis drives reactive astrocyte reactivity by stimulating the IL-6-STAT3 signaling cascade activity in astrocytes during neuroinflammation. Therefore, DLL4-NOTCH1 axis might be considered as a novel pathway inducing astrocyte reactivity and could be added to the “reactive astrocyte” nomenclature as a marker of astrocyte reactivity. It also might be interesting to look at the DLL4-NOTCH1-IL-6-STAT3 signaling cascade in other chronic disorders such as Alzheimer's and Parkinson's diseases to broaden the scope of our study.

In the vertebrates, 4 different NOTCH receptors have been identified and at the blood-brain barrier, NOTCH1 and NOTCH4 are expressed by endothelial cells [18–20] while NOTCH3 is expressed by mural cells, or pericytes [21, 22]. Importantly, DLL4 was previously established as a critical regulator of angiogenesis via the DLL4-mediated NOTCH signaling in endothelial cells which is a key pathway for vascular development [35]. During neuropathology, two interconnected and interdependent vascular processes are observed: blood-brain barrier breakdown leading to parenchymal inflammatory infiltration [46] and abnormal angiogenesis [47]. Notably, in multiple sclerosis, studies indicate that angiogenesis takes place early and show either beneficial or detrimental effect on clinical recovery depending on the literature [48]. We tested extensively whether DLL4 astrocytic upregulation during neuroinflammation leads to abnormal angiogenesis and we found no differences in blood vessel density or

mural cell coverage in astrocytic *Dll4* knockdown mice versus controls at day 18 post-induction. Within the neurovascular unit, astrocytes are not in direct contact with endothelial cells at the blood-brain barrier and therefore, any potential regulation of angiogenesis through the DLL4-NOTCH pathway during neuroinflammation would require paracrine signaling between DLL4 secreted by astrocytes and its receptor NOTCH1 at the endothelium. We performed additional experiments testing for the presence of DLL4 expressing exosomes in conditioned media from cultured IL-1 β treated human astrocytes and did not detect these. These negative results and our current neuropathological results suggest that astrocyte DLL4 upregulation drives endothelial blood-brain barrier breakdown rather than angiogenesis, via the secretion of the pro-permeability factors TYMP and VEGFA [7].

The question remains as to whether astrocytic DLL4 engages with NOTCH receptors of other cell types within the neurovascular unit, including mural cells, or pericytes, microglial processes and most interestingly, immune cells. Once immune cells penetrate the blood-brain barrier, they accumulate within the perivascular space, a region between the basal basement membrane of the endothelial cell wall and the parenchymal basement membrane abutting the astrocyte endfeet [46, 49]. The literature shows that mature naive CD4⁺ and CD8⁺ T cells express NOTCH1 and NOTCH2 receptors, with up regulated expression following T cell receptor (TCR) stimulation, and that NOTCH signaling participates in T cell differentiation. Indeed, NOTCH acts as an unbiased amplifier of T cell differentiation promoting either Th1 or Th2 responses under different polarizing conditions and it also contributes to the maintenance of the Th17 response [50]. Moreover, *in vivo* work suggests that NOTCH signaling curtails Treg function [51]. Finally, novel emerging properties of the DLL4-NOTCH signaling pathway have been identified in pathological condition, notably its role in contributing to the balance of the CD4⁺/CD8⁺, Th17/Treg ratio both in experimental autoimmune uveitis and EAE models [52, 53].

Comparing conditional *DLL4* knockout mice and controls, we found that astrocytic DLL4 promotes the entry of T cells into the CNS parenchyma in two *in vivo* models of CNS inflammation (EAE and IL-1 β cortical stereotactic injection) and that DLL4 astrocytic deletion reduces clinical disability and histopathological damage during EAE. Collectively, these results suggest that astrocytic DLL4 does not only control astrocyte reactivity but may also influence T cell trafficking behaviors and/or activation and differentiation patterns. The extent to which T cell activation and differentiation is influenced by local DLL4-NOTCH

signaling interactions within the perivascular space has yet to be determined and is currently under investigation by our group.

Exogenous administration of an anti-mouse DLL4 antibody improved the disease in wild type mice induced with EAE, but this amelioration was moderate and similar to the one observed in EAE induced *Dll4^{ACKO}* mice which have a moderate recombination in spinal cord astrocytes. The impact of the anti-mouse DLL4 antibody therapy on EAE pathology was less significant than the one observed in the *Dll4^{ACKO}* mice which are characterized by a full recombination efficacy in spinal cord astrocytes. This discrepancy on EAE disease severity observed between a complete astrocyte *Dll4* knockdown and the anti-mouse DLL4 antibody therapy may be due to several possible factors. First, the anti-mouse DLL4 antibody is injected systemically, possibly affecting DLL4 expression in other cell types with potential opposite effects on EAE pathology. While we induced EAE in *Cadherin5-Cre^{ERT2}*, *Dll4^{Flox/Flox}* mice and littermate controls and showed that *Dll4* endothelial specific downregulation has no impact on EAE disease severity, the potential still exists for effects on other unidentified cell types in adult mice induced with EAE that might express DLL4 and have opposing effects on EAE. Second, another possibility could be that the blood-brain barrier, although permeable during EAE, still displays barrier properties limiting the amount of anti-mouse DLL4 antibody accessing the perivascular space and parenchyma. A third consideration is the specificity of the *Aldh1L1-Cre* promoter to astrocytes. While prior work showed high specificity of this promoter within the CNS to astrocytes, it is possible that it induces recombination in other cell types in the body expressing *DLL4* which might contribute to the EAE phenotype [54].

Overall, our study identifies the DLL4-NOTCH1 axis as a key driver of astrocyte reactivity during neuroinflammation via the IL-6-STAT3-TYMP/VEGFA signaling pathway, which is associated with disruption of the neurovascular unit and worsening pathology. This work also raises exciting questions about the role of the DLL4-NOTCH signaling in T-cell activation and differentiation (CD4+/CD8+, Th17/Treg balance) within the perivascular spaces of the neurovascular unit and its impact on neuropathology during neuroinflammation.

In conclusion, this work highlights a novel role for the astrocyte ligand DLL4 in the driving of astrocyte reactivity and breakdown of the blood-brain barrier during neuroinflammation via juxtacrine NOTCH1 mediated signaling to neighboring astrocytes.

Abbreviations

ACKO	Astrocyte knockout
ACTB	Beta actin
ADAM	A disintegrin and metalloprotease
ALDH1L1	Aldehyde dehydrogenase 1 family member L1
CASP3	Caspase 3
CD4	Cluster of differentiation 4
CD31	Cluster of differentiation 31
CD45	Cluster of differentiation 45
CDH5	Cadherin 5
CNS	Central nervous system
DAPI	4',6-diamidino-2-phenylindole
DLL4	Delta-like 4
EAE	Experimental autoimmune encephalomyelitis
ET-1	Endothelin 1
FGB	Fibrinogen
GFAP	Glial fibrillary acidic protein
GFP	Green fluorescent protein
GLAST	Glutamate ASpartate Transporter
HES1	Hairy and enhancer of split-1
HES2	Hairy and enhancer of split-2
HEY1	Hairy/enhancer-of-split related with YRPW motif protein 1
HIV	Human immunodeficiency virus
IBA1	Ionized calcium-binding adapter molecule 1
IgG	Immunoglobulin G
IL-1 β	Interleukin-1 beta
IL-6	Interleukin-6
IL-9	Interleukin-9
IL-10	Interleukin-10
IP-10	Interferon gamma-induced protein 10
JAK	Janus kinase
MBP	Myelin basic protein
MOG	Myelin oligodendrocyte glycoprotein
MS	Multiple sclerosis
NA	Normal astrocytes (human)
NEUN	Hexaribonucleotide binding protein-3
NGF	Nerve growth factor
NICD1	Notch intracellular domain 1
NO	Nitric oxide
NOTCH1	Neurogenic locus notch homolog protein 1
PODXL	Podocalyxin
RNA	Ribonucleic acid
SMA	Smooth muscle actin
STAT3	Signal transducer and activator of transcription 3
TNF	Tumor necrosis factor
TNF α	Tumor necrosis factor alpha
TYMP	Tymidin phosphorylase
VEGFA	Vascular Endothelial Growth Factor
VIM	Vimentin

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12974-024-03246-w>.

Supplementary Material 1

Acknowledgements

We thank Sylvain Grolleau, and Maxime David for their technical help. We thank Christelle Boullé for administrative assistance.

Author contributions

P.M. and M.L. conducted experiments, acquired data and analyzed data. C.B. conducted experiments and acquired data. P.R., B. J.-V. and M. M. conducted experiments. A.-P. G., T. C., S. H. and M.-A. R. critically revised the manuscript. C.C. designed research studies, conducted experiments, acquired data, analyzed data, provided reagents, and wrote the manuscript.

Funding

Fondation pour l'aide à la recherche sur la sclérose en plaques (ARSEP), projet EMERGENCE ARSEP 2021 numéro 1246, grant R21076GG (CC, PM).

Data availability

No datasets were generated or analysed during the current study.

Declarations

Ethics approval and consent to participate

Human samples: The Neuro-CEB bio bank and the INSERM U1034 certify that all human sections utilized for this study are ethically obtained with documented, legal permission for research use (authorization number #AC-2018-3290 obtained from the Ministry of Higher Education and Research) and in the respect of the written given consent from the source person in accordance with applicable laws and the WMA Helsinki declaration of 2013. Animal experiments were performed in accordance with the guidelines from Directive 2010/63/EU of the European Parliament on the protection of animals used for scientific purposes and approved by the local Animal Care and Use Committee of the Bordeaux University CEEA50 (IACUC protocol #16901).

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Received: 4 July 2024 / Accepted: 26 September 2024

Published online: 10 October 2024

References

- McConnell HL, Kersch CN, Woltjer RL, Neuwelt EA. The translational significance of the neurovascular unit. *J Biol Chem*. 2017;20(3):762–70.
- Engelhardt B, Coisne C. Fluids and barriers of the CNS establish immune privilege by confining immune surveillance to a two-walled castle moat surrounding the CNS castle. *Fluids Barriers CNS* déc. 2011;8(1):4.
- Iadecola C. The neurovascular unit coming of age: a journey through neurovascular coupling in Health and Disease. *Neuron* 27 sept. 2017;96(1):17–42.
- Mora P, Hollier PL, Guimbal S, Abelanet A, Diop A, Cornuault L, et al. Blood-brain barrier genetic disruption leads to protective barrier formation at the Glia limitans. *PLoS Biol* Nov. 2020;18(11):e3000946.
- Liddelow SA, Olsen ML, Sofroniew MV. Reactive astrocytes and emerging roles in Central Nervous System (CNS) disorders. *Cold Spring Harb Perspect Biol*. 5 févr 2024;a041356.
- Gimsa U, Mitchison NA, Brunner-Weinzierl MC. Immune privilege as an intrinsic CNS property: astrocytes protect the CNS against T-cell-mediated neuroinflammation. *Mediators Inflamm*. 2013;2013:320519.
- Chapouly C, Tadesse Argaw A, Horng S, Castro K, Zhang J, Asp L, et al. Astrocytic TYMP and VEGFA drive blood-brain barrier opening in inflammatory central nervous system lesions. *Brain* juin. 2015;138(Pt 6):1548–67.
- Nitta T, Hata M, Gotoh S, Seo Y, Sasaki H, Hashimoto N, et al. Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. *J Cell Biol* 12 mai. 2003;161(3):653–60.
- Zhong JH, Zhou HJ, Tang T, Cui HJ, Yang AL, Zhang QM, et al. Activation of the Notch-1 signaling pathway may be involved in intracerebral hemorrhage-induced reactive astrogliosis in rats. *J Neurosurg* sept. 2018;129(3):732–9.
- Shimada IS, Borders A, Aronshtam A, Spees JL. Proliferating reactive astrocytes are regulated by Notch-1 in the peri-infarct area after stroke. *Stroke* nov. 2011;42(11):3231–7.
- Nonneman A, Criem N, Lewandowski SA, Nuyts R, Thal DR, Pfrieger FW, et al. Astrocyte-derived Jagged-1 mitigates deleterious notch signaling in amyotrophic lateral sclerosis. *Neurobiol Dis* Nov. 2018;119:26–40.
- Cheng YY, Ding YX, Bian GL, Chen LW, Yao XY, Lin YB, et al. Reactive astrocytes display pro-inflammatory adaptability with modulation of Notch-P13K-AKT signaling pathway under inflammatory stimulation. *Neurosci* 1 août. 2020;440:130–45.
- Liu X, Zhou F, Wang W, Chen G, Zhang Q, Lv R, et al. IL-9-triggered lncRNA Gm13568 regulates Notch1 in astrocytes through interaction with CBP/P300: contribute to the pathogenesis of experimental autoimmune encephalomyelitis. *J Neuroinflammation* déc. 2021;18(1):1–15.
- Fortini ME. Gamma-secretase-mediated proteolysis in cell-surface-receptor signalling. *Nat Rev Mol Cell Biol* sept. 2002;3(9):673–84.
- Selkoe D, Kopan R. Notch and presenilin: regulated intramembrane proteolysis links development and degeneration. *Annu Rev Neurosci*. 2003;26:565–97.
- Mumm JS, Kopan R. Notch signaling: from the outside in. *Dev Biol* 15 déc. 2000;228(2):151–65.
- Bray SJ. Notch signalling: a simple pathway becomes complex. *Nat Rev Mol Cell Biol* sept. 2006;7(9):678–89.
- Murphy PA, Lam MTY, Wu X, Kim TN, Vartanian SM, Bollen AW, et al. Endothelial Notch4 signaling induces hallmarks of brain arteriovenous malformations in mice. *Proc Natl Acad Sci U S A* août. 2008;105(31):10901–6.
- Grigorian A, Hurford R, Chao Y, Patrick C, Langford TD. Alterations in the Notch4 pathway in cerebral endothelial cells by the HIV aspartyl protease inhibitor, nelfinavir. *BMC Neurosci* déc. 2008;9(1):1–18.
- Yu L, Lu Z, Burchell S, Nowrangi D, Manaenko A, Li X, et al. Adropin preserves the blood-brain barrier through a Notch1/Hes1 pathway after intracerebral hemorrhage in mice. *J Neurochem* déc. 2017;143(6):750–60.
- Liu H, Kennard S, Lilly B. NOTCH3 expression is induced in mural cells through an autoregulatory loop that requires endothelial-expressed JAGGED1. *Circ Res* 27 févr. 2009;104(4):466–75.
- Gaengel K, Genové G, Armulik A, Betsholtz C. Endothelial-mural cell signaling in vascular development and angiogenesis. *Arterioscler Thromb Vasc Biol* Mai. 2009;29(5):630–8.
- Qian D, Li L, Rong Y, Liu W, Wang Q, Zhou Z, et al. Blocking notch signal pathway suppresses the activation of neurotoxic A1 astrocytes after spinal cord injury. *Cell Cycle* nov. 2019;18(21):3010–29.
- Patel M, Anderson J, Lei S, Finkel Z, Rodriguez B, Esteban F, et al. Nkx6.1 enhances neural stem cell activation and attenuates glial scar formation and neuroinflammation in the adult injured spinal cord. *Exp Neurol* Nov. 2021;345:113826.
- Ribeiro TN, Delgado-García LM, Porcionatto MA. Notch1 and Galectin-3 modulate cortical reactive astrocyte response after Brain Injury. *Front Cell Dev Biol*. 2021;9:649854.
- MacGrogan D, Münch J, de la Pompa JL. Notch and interacting signalling pathways in cardiac development, disease, and regeneration. *Nat Rev Cardiol* Nov. 2018;15(11):685–704.
- Alexandre PA-RT, Ana-Carina F, Catarina C, Joana G, Teresa TA et al. Endothelial Jagged1 Antagonizes Dll4 Regulation of Endothelial Branching and Promotes Vascular Maturation Downstream of Dll4/Notch1. *Arteriosclerosis, Thrombosis, and Vascular Biology*. 1 mai. 2015;35(5):1134–46.
- Escartin C, Galea E, Lakatos A, O'Callaghan JP, Petzold GC, Serrano-Pozo A, et al. Reactive astrocyte nomenclature, definitions, and future directions. *Nat Neurosci* mars. 2021;24(3):312–25.
- Wagner DC, Riegelberger UM, Michalk S, Härtig W, Kranz A, Boltze J. Cleaved caspase-3 expression after experimental stroke exhibits different phenotypes and is predominantly non-apoptotic. *Brain Res* 24 mars. 2011;1381:237–42.
- Wongchana W, Palaga T. Direct regulation of interleukin-6 expression by notch signaling in macrophages. *Cell Mol Immunol* mars. 2012;9(2):155–62.
- Liu Y, Gibson SA, Benveniste EN, Qin H. Opportunities for translation from the Bench: therapeutic intervention of the JAK/STAT pathway in Neuroinflammatory diseases. *Crit Rev Immunol*. 2015;35(6):505–27.
- Reichenbach N, Delekate A, Plescher M, Schmitt F, Krauss S, Blank N, et al. Inhibition of Stat3-mediated astrogliosis ameliorates pathology in an Alzheimer's disease model. *EMBO Mol Med* févr. 2019;11(2):e9665.
- Abjean L, Ben Haim L, Riquelme-Perez M, Gipchtein P, Derbois C, Palomares MA et al. Reactive astrocytes promote proteostasis in Huntington's disease through the JAK2-STAT3 pathway. *Brain*. 17 mars 2022;awac068.
- Ceyzériat K, Abjean L, Carrillo-de Sauvage MA, Ben Haim L, Escartin C. The complex STATs of astrocyte reactivity: how are they controlled by the JAK-STAT3 pathway? *Neuroscience*. 25 août. 2016;330:205–18.
- Hellström M, Phng LK, Hofmann JJ, Wallgard E, Coultas L, Lindblom P, et al. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. *Nat* 15 févr. 2007;445(7129):776–80.
- de Sena Brandine G, Smith AD. Falco: high-speed FastQC emulation for quality control of sequencing data. *F1000Res*. 2019;8:1874.
- Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinf* 1 août. 2014;30(15):2114–20.
- Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. *Bioinf* 1 janv. 2013;29(1):15–21.

39. Gurfein BT, Zhang Y, López CB, Argaw AT, Zameer A, Moran TM, et al. IL-11 regulates autoimmune demyelination. *J Immunol* 1 oct. 2009;183(7):4229–40.
40. Vainchtein ID, Alsema AM, Dubbelaar ML, Grit C, Vinet J, van Weering HRJ, et al. Characterizing microglial gene expression in a model of secondary progressive multiple sclerosis. *Glia* mars. 2023;71(3):588–601.
41. Notch signaling as a master regulator of adult neurogenesis - PubMed. [cité 5 sept 2024]. Disponible sur: <https://pubmed-ncbi-nlm-nih-gov.proxy.insermbiblio.inist.fr/37457009/>
42. Choi SS, Lee HJ, Lim I, Satoh Jichi, Kim SU. Human astrocytes: Secretome profiles of cytokines and chemokines. *PLOS ONE* 1 avr. 2014;9(4):e92325.
43. Dong Y, Benveniste EN. Immune function of astrocytes. *Glia* Nov. 2001;36(2):180–90.
44. Farina C, Aloisi F, Meinl E. Astrocytes are active players in cerebral innate immunity. *Trends Immunol mars*. 2007;28(3):138–45.
45. Nakamachi T, Tsuchida M, Kagami N, Yofu S, Wada Y, Hori M, et al. IL-6 and PACAP receptor expression and localization after global brain ischemia in mice. *J Mol Neurosci* Nov. 2012;48(3):518–25.
46. Engelhardt B, Ransohoff RM. Capture, crawl, cross: the T cell code to breach the blood-brain barriers. *Trends Immunol déc*. 2012;33(12):579–89.
47. Girolamo F, Coppola C, Ribatti D, Trojano M. Angiogenesis in multiple sclerosis and experimental autoimmune encephalomyelitis. *Acta Neuropathol Commun* 22 Juill. 2014;2(1):84.
48. Lengfeld J, Cutforth T, Agalliu D. The role of angiogenesis in the pathology of multiple sclerosis. *Vasc Cell*. 2014;6(1):23.
49. Engelhardt B, Coisne C. Fluids and barriers of the CNS establish immune privilege by confining immune surveillance to a two-walled castle moat surrounding the CNS castle. *Fluids Barriers CNS*. 18 janv. 2011;8(1):4.
50. Keerthivasan S, Suleiman R, Lawlor R, Roderick J, Bates T, Minter L, et al. Notch signaling regulates mouse and human Th17 differentiation. *J Immunol* 15 Juill. 2011;187(2):692–701.
51. Brandstadter JD, Maillard I. Notch signalling in T cell homeostasis and differentiation. *Open Biol* 6 Nov. 2019;9(11):190187.
52. Eixarch H, Mansilla MJ, Costa C, Kunkel SL, Montalban X, Godessart N, et al. Inhibition of delta-like ligand 4 decreases Th1/Th17 response in a mouse model of multiple sclerosis. *Neurosci Lett* 29 avr. 2013;541:161–6.
53. Yin X, Liu B, Wei H, Wu S, Guo L, Xu F, et al. Activation of the notch signaling pathway disturbs the CD4+/CD8+, Th17/Treg balance in rats with experimental autoimmune uveitis. *Inflamm Res sept*. 2019;68(9):761–74.
54. Nemeth D, Luqman N, Chen L, Quan N. Aldh111-Cre/ER T2 is expressed in unintended cell types of the salivary gland, pancreas, and spleen. *MicroPubl Biol*. 2023. <https://doi.org/10.17912/micropub.biology.000832>

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.